Psoriatic arthritis is a type of inflammatory arthritis that develops in some people who have psoriasis, a chronic skin condition characterized by red, scaly patches. While psoriasis affects the skin, psoriatic arthritis targets the joints, causing pain, swelling, stiffness, and reduced mobility. It can develop years before or after psoriasis appears, and in some cases, joint symptoms may be the first sign. This condition varies significantly from person to person - some experience mild symptoms affecting only a few joints, while others face more severe, progressive disease that impacts multiple joints and can affect the spine, tendons, and other tissues.

Bimekizumab is a monoclonal antibody treatment that has shown significant promise in managing psoriatic arthritis. It works by targeting and blocking IL-17A and IL-17F, cytokines that play a key role in driving inflammation in psoriatic arthritis. This dual inhibition approach can reduce joint pain and swelling, improve mobility, and slow progression of the disease. Like all biologic treatments, bimekizumab carries potential side effects - the most common include upper respiratory infections, nasopharyngitis, and oral candidiasis (thrush). More serious but less frequent side effects can include severe infections, tuberculosis reactivation, and inflammatory bowel disease complications. Regular monitoring and screening for infections and tuberculosis are important safety measures when using this treatment.